www.3sbio.com 提示:

本信息仅供医学专业人士参考,如果您是医学专业人士,请点击确定后进入。 如果不是,请点击取消。

取消 确定

Products and services

In 3SBio, meeting the needs of patients is the core of all actions.

Our global list of drug combinations

The following is a list of products listed by our company, which is only for medical professionals to refer to.

YISAIPU (Recombinant human type II tumor necrosis factor receptor - antibody fusion protein)

YISAIPU was marketed in 2005 and is the first antibody fusion protein medicine marketed in the rheumatism field of China. 3 kinds of indications were approved by the NMPA: Treatment of rheumatoid arthritis (approved in 2005), ankylosing spondylitis and psoriasis (approved in 2007). It is included in the National Medical Insurance Catalogue as a Category B drug of western medicine.

Indication Manufacturing base Dosage form & Dosage
Moderate to severe rheumatoid arthritis;
Moderate to severe plaque psoriasis (PS) in adults aged 18 or above;
Active ankylosing spondylitis.
Shanghai manufacturing base 12.5 mg/bottle; 25 mg/bottle